Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(Deep Venous Thrombosis)
82,416 results
  • StatPearls: Streptokinase [BOOK]
    StatPearls Publishing: Treasure Island (FL) Edwards Zachary Z Campbell University School of Osteopathic Medicine Nagalli Shivaraj S Yuma Regional Medical Center BOOK
  • The activation of the coagulation cascade is multifactorial. Clot formation can occur due to venous stasis, hypercoagulable states such as malignancy, or endothelial injury. These conditions activate the coagulation cascade, which ultimately leads to the development of a fibrin clot. Streptokinase is FDA approved in the treatment of acute ST-segment elevation myocardial infarction, arterial throm…
  • StatPearls: Splenic Venous Thrombosis [BOOK]
    StatPearls Publishing: Treasure Island (FL) Akhondi Hossein H University of Nevada Ganjali Shirin S Tuma Faiz F Central Michigan University BOOK
  • Clotting of blood in these venous systems can lead to splanchnic venous thrombosis. It includes thrombosis in the splenic vein, mesenteric vein, portal vein, or hepatic vein (Budd-Chiari syndrome). The most common site of venous thrombosis is portal vein and mesenteric vein, and the least common is the hepatic vein.[1] Splanchnic venous thrombosis can lead to different symptoms, and its presentat…
  • How I Manage Cancer-Associated Thrombosis. [Journal Article]
    Hamostaseologie 2020Moik F, Ay C
  • In this concise review, we discuss some common clinical challenges in the management of patients with cancer-associated venous thromboembolism (VTE), a frequent complication in patients with cancer that increases morbidity and mortality. While direct oral anticoagulants (DOACs) have been established in clinical practice for anticoagulation in patients with VTE without cancer, their efficacy and s…
  • Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer. [Journal Article]
    Hematology 2020; 25(1):63-70Wang Y, Wang M, … Liang Z
  • CONCLUSIONS: DOACs are effective for thromboprophylaxis in ambulatory cancer patients, but there is a potential risk of bleeding. DOACs may be recommended in selected patients at high risk of VTE. More high-quality studies are needed to further validate our results.Abbreviations: CAT: cancer-associated thrombosis; CI: confidence interval; DOAC: direct oral anticoagulant; DVT: deep vein thrombosis; LMWH: low molecular weight heparin; NNH: number needed to harm; NNT: number needed to treat; PE: pulmonary embolism; RCT: randomized controlled trials; RR: risk ratio; RD: rate difference; VTE: venous thromboembolism.
New Search Next